Total neoadjuvant therapy vs standard therapy in locally advanced rectal cancer: a systematic review and meta-analysis
Importance Standard therapy for locally advanced rectal cancer includes concurrent
chemoradiotherapy followed by surgery and adjuvant chemotherapy (CRT plus A). An …
chemoradiotherapy followed by surgery and adjuvant chemotherapy (CRT plus A). An …
[HTML][HTML] Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis …
Background PARP inhibitors (PARPi) have recently been approved for various malignancies
based on the results of several clinical trials. However, these trials have mostly recruited …
based on the results of several clinical trials. However, these trials have mostly recruited …
ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin …
R Metzger, CG Leichman, KD Danenberg… - Journal of Clinical …, 1998 - ascopubs.org
PURPOSE We have previously shown that relative thymidylate synthase (TS) mRNA levels
in primary gastric adenocarcinomas treated with fluorouracil (5-FU) and cisplatin are …
in primary gastric adenocarcinomas treated with fluorouracil (5-FU) and cisplatin are …
Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil …
CG Leichman, HJ Lenz, L Leichman… - Journal of clinical …, 1997 - ascopubs.org
PURPOSE Response rates to fluorouracil (5-FU)-based therapy remain low. As new, active
agents are being tested, information regarding specific intratumoral genetic determinants of …
agents are being tested, information regarding specific intratumoral genetic determinants of …
Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.
HJ Lenz, CG Leichman, KD Danenberg… - Journal of Clinical …, 1996 - ascopubs.org
PURPOSE We tested the hypothesis that polymerase chain reaction (PCR) quantitation of
the enzyme thymidylate synthase (TS) within a primary adenocarcinoma of the stomach, has …
the enzyme thymidylate synthase (TS) within a primary adenocarcinoma of the stomach, has …
[HTML][HTML] EV-101: A phase I study of single-agent enfortumab vedotin in patients with nectin-4–positive solid tumors, including metastatic urothelial carcinoma
J Rosenberg, SS Sridhar, J Zhang, D Smith… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE To assess the safety/tolerability and antitumor activity of enfortumab vedotin (EV),
a novel investigational antibody-drug conjugate that delivers the microtubule-disrupting …
a novel investigational antibody-drug conjugate that delivers the microtubule-disrupting …
Phase 2 study of MK‐2206, an allosteric inhibitor of AKT, as second‐line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative …
RK Ramanathan, SL McDonough, HF Kennecke… - Cancer, 2015 - Wiley Online Library
BACKGROUND The AKT inhibitor MK‐2206 at a dose of 60 mg every other day was
evaluated in gastric/gastroesophageal junction cancers. METHODS Patients who had …
evaluated in gastric/gastroesophageal junction cancers. METHODS Patients who had …
[HTML][HTML] Capecitabine versus 5-fluorouracil in colorectal cancer: where are we now?
L Chintala, S Vaka, J Baranda, SK Williamson - Oncology Reviews, 2011 - Springer
Abstract Fluorouracil (5-FU) remains the most widely used agent for colorectal cancer.
Capecitabine is a rationally designed 5-FU pro-drug developed to mimic the continuous …
Capecitabine is a rationally designed 5-FU pro-drug developed to mimic the continuous …
[HTML][HTML] PD-1 blockade in recurrent or metastatic cervical cancer: data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in …
D Rischin, M Gil-Martin, A González-Martin, I Braña… - Gynecologic …, 2020 - Elsevier
Objectives To characterize the safety, tolerability, and anti-tumor activity of cemiplimab as
monotherapy or in combination with hypofractionated radiation therapy (hfRT) in patients …
monotherapy or in combination with hypofractionated radiation therapy (hfRT) in patients …
[PDF][PDF] Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results
This is the phase Ib part of the phase I/II CAMILLA trial evaluating cabozantinib plus
durvalumab in advanced chemo-refractory proficient mismatch repair or microsatellite stable …
durvalumab in advanced chemo-refractory proficient mismatch repair or microsatellite stable …